A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients

BACKGROUND: Activation of the vascular endothelial growth factor receptor (VEGFR) and the oncogenic Src pathway has been implicated in the development of castration-resistant prostate cancer (CRPC) in preclinical models. Cediranib and dasatinib are multi-kinase inhibitors targeting VEGFR and Src res...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Invest New Drugs
Auteurs principaux: Spreafico, Anna, Chi, Kim N., Sridhar, Srikala S., Smith, David C., Carducci, Michael A., Kavsak, Peter, Wong, Tracy S., Wang, Lisa, Ivy, S. Percy, Mukherjee, Som Dave, Kollmannsberger, Christian K., Sukhai, Mahadeo A., Takebe, Naoko, Kamel-Reid, Suzanne, Siu, Lillian L., Hotte, Sebastien J.
Format: Artigo
Langue:Inglês
Publié: 2014
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4281773/
https://ncbi.nlm.nih.gov/pubmed/24788563
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-014-0106-5
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires